ABSTRACT A series of 252 isolated aortic homograft valves in 248 patients have been followed for 9 to 16.5 years (mean 10.8 
FREEHAND INSERTION of an aortic homograft valve in the subcoronary position was first performed in 1962. 1 ' 2 The earliest valves inserted at Green Lane Hospital were collected by sterile technique (untreated or fresh valves) but for logistic reasons sterile collection was soon replaced by chemical sterilization of valves removed at routine autopsy. Chemical sterilization was abandoned in August 1968 because of the high incidence of valve failure and was replaced with the antibiotic sterilized aortic homograft valve (ASAHV). 3 The short-and midterm clinical results with the ASAHV were superior to those with chemical sterilization and similar to those with untreated homograft valves. 4 The purpose of this report is to analyze the late follow-up results of the ASAHV, with particular reference to the incidence and causes of homograft valve failure.
THERAPY AND PREVENTION-VALVE REPLACEMENT (19%) had evidence of congestive heart failure. The electrocardiogram showed severe left ventricular hypertrophy in 200 patients, moderate hypertrophy in 34 patients, and less than moderate hypertrophy in the remainder.
Sixty-one (24%) had had previous operations on their aortic valves, which included homograft valve replacement (n = 55), prosthetic valve replacement (n = 2), valvotomy (n = 3), and Bahnson leaflets (n = 1). Associated lesions included proven coronary artery disease (n = 16), ventricular septal defect (n = 3), coarctation (n = 6), and patent ductus arteriosus (n = 1). Routine coronary arteriography was not undertaken over the period that these patients were operated on.
Surgical technique. The surgical technique for freehand insertion of the ASAHV has remained essentially unchanged throughout our experience and uses double continuous suture lines to approximate the upper and lower cut margins of the aortic wall remnant of the graft to the host aortic root5 plus vertical mattress sutures beneath the valve commissures to obliterate the major portion of dead space between graft and host. 6 Aortic root tailoring, which involved excision of a wedge of the aortic root5 to allow a proper match with the available homograft valve when the root was excessively large (or occasionally when larger valves were unavailable) was done in 19 patients (7.5%). The myocardium was protected during the period of aortic cross-clamping by continuous perfusion of both coronary arteries with blood at 300 C. Every effort was made to keep the heart beating throughout the procedure.
Homograft valve preparation. The 252 aortic valves were obtained from 160 male and 71 female cadaver donors. Donor sex was not recorded in 21 instances. Donor age ranged from 11 to 73 years. In particular, seven donors were over 65 and 28 were 55 to 65 years old. The commonest causes of donor death were trauma (n = 147), malignancy (n = 24), and poisons or drugs (n = 20) . Almost all causes of death were accepted other than septicemia and jaundice. The salvage time between death of the donor and autopsy was under 24 hr in 114, 24 dal infection (Torulopsis glabrata) first recognized 12 months postoperatively and subsequently cured with antibiotics and reoperation. 10 The patient died of heart failure 6 months after the second homograft valve was inserted, secondary to extensive embolic coronary artery occlusions and infarctions. At no time was there significant incompetence. Another patient with bacterial endocarditis died of embolic cerebral abscess, also without significant incompetence. None of the other six patients dying from active endocarditis and significant incompetence were referred for consideration of reoperation, and in only two was this management justified by the presence of severe cerebral complications. The seven patients who underwent reoperation for significant incompetence due to endocarditis (one still active and six subsequent to abolition of the infec- perivalvar leak, which, per se, was very rare (one patient), and it did not occur before 11 months postoperatively. Moreover, adequate antibiotic treatment usually cured the infection. The incidence of homograft valve endocarditis was similar with first, second, and third operations. The actuarial analyses of the donor factors affecting the incidence of significant incompetence due to valve wear (excluding, therefore, bacterial endocarditis and peripheral leak) indicated no significant differences in donor sex, donor valve salvage time, or type of storage medium. Storage time was of borderline significance, with freedom from significant incompetence of 88% at 10 years when storage time was under 20 days and 65% when it exceeded 50 days (p = .06). the results were also less good when minor imperfections were present, with freedom from significant incompetence of 81% at 10 years when the donor valve was perfect compared with 59% when imperfections were present (figure 4), but this difference was not significant (p = .2). A highly significant factor was donor age (figure 5), with freedom from significant incompetence of 94% at 10 years when donor age was less than 20 years (representing only two examples of leaflet rupture at 106 and 113 months amongst 48 patients) and 62% when donor age was over 50 years.
Actuarial analysis of recipient factors affecting the development of significant incompetence indicated that a large aortic root became important (figure 6) when the diameter exceeded 30 mm (aortic root size being 2 mm larger than the internal diameter of the homograft valve). The diameters were those recorded after aortic root tailoring, which was performed in 19 patients. Significant incompetence due to valve wear (excluding endocarditis and peripheral leak) occurred in only three (18%) of the 17 survivors, indicating a satisfactory long-term result in this subset, particularly as the four patients alive with the study valve in situ at the time of censoring had either absent (n = 3) or only mild (n = 1) incompetence. Significant incompetence was more common in patients under 20 years of age, but the numbers in this group were small and the differences not significant on this type of analysis. Patients with aortic inc6mpetence fared slightly worse than those with aortic stenosis or a combined lesion (p = .03). The degree of aortic root calcification, a previous aortic valve operation (almost all had been homograft procedures), or recipient sex or race did not influence the incidence of significant incompetence. On multivariate analysis the significant variables increasing the incidence of significant incompetence due to valve wear were donor age, aortic root size, and recipient age (table 4). Donor age was highly significant as a continuous variable (p = .004) and as a yes/no variable (> 50 years). However, the best split occurred at 55 years and older (p = .0002). Aortic root size was also significant as a continuous variable (p = .002), but the best split occurred at over 30 mm (corresponding to a homograft valve internal diameter of > 28 mm) (p = .0007). Recipient age was not significant as a continuous variable. It was of borderline significance when considered as a yes/no variable (< 20 years; p = .04) and only highly so when age was under 15 years. In fact, there were only five such patients (children), three of whom developed cusp rupture at 32, 59, and 118 months postoperatively. Leaflet calcification was not present. One of these had received a valve from a 60-year-old donor, presumably because a young valve was not available. In the total group, there was a weak relationship between patient age and donor age.
Those patients over 14 years of age who received a homograft valve from a donor under 50 years of age and with an internal diameter of 28 mm or less (aortic root diameter . 30 mm) were grouped together as those least likely to develop significant incompetence due to valve wear (low-risk group). Twenty-six of these 144 patients, who composed 61% of the study group, developed significant incompetence at 44 to 181 months (mean 115) follow-up. The actuarial incidence of freedom from significant incompetence was 98% at 5 years, 87% at 10 years, and 62% at 13 years (figure 7) . In this group of patients there was a sharp increase in the incidence of significant incompetence after 9 years, for at 9 years the incidence-free figure was a striking 94% (t 2.3). In contrast, the 93 patients who were either under 15 years of age or who for significant homograft valve incompetence was reoperation or death from this cause rather than its first appearance means that most classed as moderate were patients still alive without reoperation at last followup. This is the main explanation for the differences between the actuarial incidence of reoperation vs significant incompetence in patients followed beyond 10 years.
The in-hospital mortality in this precardioplegic era was low overall (6%) but high (50%) in the 16 emergency procedures. For the entire set of homograft operations (n = 393) for the time frame under consideration (1968 to 1974) the mortality for emergency procedures (n = 26) was 38%. These figures can be compared with the in-hospital mortality for the current cardioplegic era (1980 to 1986, n = 348) of 1.7% overall and 12.5% for emergency procedures (n = 16). The slightly longer time taken to insert a homograft valve when compared with a prosthetic device is not considered to be a contraindication to its use in emergency situations.
The late survival of patients with the study homograft valve in situ (that is, censoring each patient having a reoperation when this occurred) is very similar to that reported for the Starr-Edwards valve,11 although such comparisons are not valid unless patient selection is similar.12 Of particular interest is the number of patients dying from valve-related complications. In contrast to a prosthetic valve, for which valve-related deaths have a variety of causes (thromboembolism, valve occlusion, hemorrhage from anticoagulants, structural failure, and early and late endocarditis), the only homograft valve complication leading to death (as well as morbidity) is the appearance of significant incompetence. Fortunately, when caused by valve wear, this failure mode is benign, and late-appearing aortic diastolic murmurs may be associated with mild incompetence for 2 or more years before progressing. Thus, in contrast to the bioprosthetic porcine glutaralehydetreated device, the late onset of a diastolic murmur is not an indication for early reoperation, which should be delayed until the leak is significant. Moreover, the mortality of reoperation has been low in our hands since 1974.13
In this series, only 8.4% of the hospital survivors died later from significant incompetence. It is of interest that four of these 20 deaths were caused by late endocarditis that was improperly managed, so that currently such deaths should be less frequent. Moreover, six other deaths occurred in elderly patients in whom reoperation for significant incompetence was not considered appropriate. This might be considered by some as a contraindication to the selection of a homograft in elderly patients rather than a more durable prosthesis.
It is thought to be justified not to attribute death from stroke in these patients to thromboembolism for the reason that thrombus has never been found in relation to a homograft valve in this or other reported series.'4 15 The figure of 3.8% late death from stroke in an elderly group of patients is not untoward and suggests that a similar percentage of stroke deaths occurring in elderly patients with prosthetic valves may not be thromboembolic in origin. This present series would also suggest that late sudden death is not thromboembolic in origin but is due to arrhythmia, ischemia, or some other mechanism.
Significant homograft valve stenosis has not occurred in this series because the valve can be inserted in small aortic roots without a gradient and because leaflet calcification is uncommon4 and, when present, occurs as discrete, small, bony, cauliflower-like spicules that have only a minor effect on leaflet movement. They predispose, however, to leaflet rupture, so that the patient presents with incompetence rather than stenosis. In contrast to the leaflets, the aortic wall remnant of the valve graft often calcifies in egg-shell fashion and this may make its removal at reoperation difficult and tedious. Homograft valve incompetence has a variety of mechanisms. 20 Rupture is a wear phenomenon occurring at the sites of greatest stress and strain, i.e., the leaflet belly and the commissures.2`It can be postulated that it is more likely to occur when the commissural leaflet tissue is weakened by congenital fenestrations and when the valve has been imperfectly placed by the surgeon (the valve is twisted or too small for the root) or the aortic root subsequently dilates so that the leaflets are poorly supported centrally at the moment of closure and tend to prolapse. Thus, although no attempt has been made to assess this factor in this analysis, it is highly likely that the valves that function the longest are those that are perfectly positioned. Incompetence has been categorized as due to a "central leak" only when the leaflets remained intact despite the increased stresses resulting from imperfect placement, aortic root dilatation, or both. Others In comparing the incidence of valve failure between the ASAHV inserted freehand and a stented porcine or pericardial tissue valve, several points need emphasis. First, the incidence of tissue failure with a bioprosthesis is inversely related to patient age at implantation, and within 10 years of operation has been estimated to be at least 30% at age 20 years, 15% at age 40, and 10% at age 60. 35 In contrast, with a homograft, patient age is possibly a risk factor only in children. Second, follow-up studies of bioprostheses that report only a reoperation rate are misleading because they exclude patients dying without reoperation or awaiting reoperation. Thus, in this report 32% of patients were found to have valve failure (significant incompetence) from all causes, but only 22% underwent reoperation. Third, it is inappropriate when reporting valve failure with a bioprosthesis to exclude cases of perivalvular leak and endocarditis, since both are related to the presence of the stent and its cloth-covered sewing ring; for this reason alone, both are much more common with a bioprosthesis than with a freehand homograft valve.36' 37 The report by Gallo et al.38 provides a 5 year incidence of tissue failure in porcine valves of 4% and a 9 year incidence of 24% (63 instances in 794 patients). The incidence was similar for valves in the aortic and mitral positions. However, only 1. 3% of the patients were under 20 years of age, and valve failure due to infection (n = 33) and perivalvular leak (n = 27) were excluded. The 5 year incidence of hemodynamically important degeneration in bioprostheses reported by Williams et al.39 was 18%. It is likely that the failure rate from all causes for bioprostheses is at least three times higher at 9 to 10 years than for the unstented homograft. Finally, when making these comparisons the absence of morbidity other than significant incompetence with a homograft valve is important, since a bioprosthesis without anticoagulants is likely to cause thromboembolism, and occasional thrombotic occlusion and hemolysis can be associated with a perivalvular leak. Moreover, a porcine aortic valve of less than 23 mm diameter has a significant gradient, which is not present with a homograft valve.4 '29 Conclusions. The ASAHV is a satisfactory device for aortic valve replacement and in our clinic remains the valve of choice for almost all patients. Donor valve age should be less than 50 years and the aortic root size should be 30 mm ing to less than 30 mm. Although the results may be less satisfactory in children, we continue to prefer the ASAHV in this age group.
